Lifecore Biomedical Management

Management criteria checks 3/4

Lifecore Biomedical's CEO is Jim Hall, appointed in Aug 2022, has a tenure of 1.67 years. total yearly compensation is $1.76M, comprised of 27.5% salary and 72.5% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $336.98K. The average tenure of the management team and the board of directors is 2.3 years and 3.5 years respectively.

Key information

Jim Hall

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage	27.5%
CEO tenure	1.7yrs
CEO ownership	0.2%
Management average tenure	2.3yrs
Board average tenure	3.5yrs

Recent management updates

Recent updates

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Apr 20

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Apr 08

Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet

Mar 21

Here's What's Concerning About Landec's (NASDAQ:LNDC) Returns On Capital

Nov 30

Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products

Nov 05

Landec Still In Play As An Activist Investment

Aug 20

Is Landec (NASDAQ:LNDC) Using Too Much Debt?

May 25

Is Landec (NASDAQ:LNDC) Using Too Much Debt?

Feb 24

The CEO, President & Director of Landec Corporation (NASDAQ:LNDC), Albert Bolles, Just Bought 38% More Shares

Jan 20

CEO Compensation Analysis

How has Jim Hall's remuneration changed compared to Lifecore Biomedical's earnings?
Date	Total Compensation	Salary	Company Earnings
May 28 2023	US$2m	US$485k	-US$64m
Feb 26 2023	n/a	n/a	-US$87m
Nov 27 2022	n/a	n/a	-US$78m
Aug 28 2022	n/a	n/a	-US$67m
May 29 2022	US$913k	US$380k	-US$15m
Feb 27 2022	n/a	n/a	-US$12m
Nov 28 2021	n/a	n/a	-US$7m
Aug 29 2021	n/a	n/a	-US$6m
May 30 2021	US$861k	US$365k	-US$23m
Feb 28 2021	n/a	n/a	-US$24m
Nov 29 2020	n/a	n/a	-US$34m
Aug 30 2020	n/a	n/a	-US$44m
May 31 2020	US$960k	US$342k	-US$22m
Feb 23 2020	n/a	n/a	-US$23m
Nov 24 2019	n/a	n/a	-US$10m
Aug 25 2019	n/a	n/a	-US$3m
May 26 2019	US$843k	US$294k	US$2m
Feb 24 2019	n/a	n/a	US$8m
Nov 25 2018	n/a	n/a	US$23m
Aug 26 2018	n/a	n/a	US$24m
May 27 2018	US$1m	US$285k	US$26m

Compensation vs Market: Jim's total compensation ($USD1.76M) is about average for companies of similar size in the US market ($USD1.62M).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.

CEO

Jim Hall (60 yo)

1.7yrs

Tenure

US$1,764,213

Compensation

Mr. James G. Hall, also known as Jim, serves as Chief Executive Officer & Director at Landec Corporation since August 10, 2022 and also serves as its President. He was President of Lifecore since June 2017...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James Hall	CEO, President & Director	1.7yrs	US$1.76m	0.17% $ 337.0k
John Morberg	Executive VP & CFO	3.3yrs	US$927.10k	0.10% $ 201.9k
Albert Bolles	President of Curation Foods	1.7yrs	US$1.34m	0.24% $ 480.7k
Steve Laninga	Vice President of Operations	4.3yrs	no data	no data
Kipling Thacker	VP & Chief Scientist	less than a year	no data	no data
Aaron Perlitsh	Director of Internal Audit & Chief Compliance Officer	no data	no data	no data
Darren Hieber	Senior Vice President of Corporate Development & Partnerships	2.3yrs	no data	no data
Kara Morley	Senior Vice President of Human Resources	2.3yrs	no data	no data
Jackie Klecker	Executive VP & GM	2.3yrs	no data	no data
Matt Augustson	Senior Vice President of Information Technology	2.3yrs	no data	no data
Parker Javid	Vice President	no data	US$460.69k	no data

2.3yrs

Average Tenure

60yo

Average Age

Experienced Management: LFCR's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
James Hall	CEO, President & Director	1.7yrs	US$1.76m	0.17% $ 337.0k
Nelson Obus	Independent Director	5.5yrs	US$180.00k	0.23% $ 465.0k
Katrina Houde	Independent Director	4.7yrs	US$185.00k	0.14% $ 275.2k
Jeffrey Edwards	Independent Director	3.5yrs	US$183.33k	0.10% $ 207.6k
Joshua Schechter	Independent Director	3.5yrs	US$170.00k	0.14% $ 273.6k
Christopher Kiper	Director	1.3yrs	no data	no data
Raymond Diradoorian	Independent Director	2.3yrs	US$50.00k	0.071% $ 143.7k
Craig Barbarosh	Independent Chairman	4.5yrs	US$255.00k	0.13% $ 263.1k
Nathaniel Calloway	Director	1.3yrs	no data	0.092% $ 185.1k

3.5yrs

Average Tenure

60yo

Average Age

Experienced Board: LFCR's board of directors are considered experienced (3.5 years average tenure).

Lifecore Biomedical Management

Management criteria checks 3/4

Key information

Recent management updates

Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024

High number of new directors

Landec Corporation, Annual General Meeting, Nov 01, 2022

VP & President of Lifecore exercised options to buy US$76k worth of stock.

Independent Director exercised options to buy US$70k worth of stock.

CEO, President & Director exercised options to buy US$269k worth of stock.

Recent updates

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024

Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024

Lifecore Biomedical Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?

Lifecore Biomedical, Inc.(NasdaqGS:LFCR) dropped from Russell 2000 Dynamic Index

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 86% to US$2.00

High number of new directors

Lifecore Biomedical Receives A Notification Letter from Nasdaq Due to Delay in Filing Its Quarterly Report on Form 10-Q for the Period Ended November 27, 2022

Lifecore Biomedical, Inc. announced that it has received $38.75 million in funding from Legion Partners Asset Management, LLC, 22NW, LP, 325 Capital, LLC, Cove Street Partners, Wynnefield Capital, Inc.

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. announced that it has received $5.003136 million in funding

Price target decreased to US$13.75

Landec Corporation Reiterates Revenue Guidance for the Full Year Fiscal 2023

Landec Non-GAAP EPS of -$0.32, revenue of $43.35M

Landec Corporation to Report Q1, 2023 Results on Oct 06, 2022

Landec Corporation, Annual General Meeting, Nov 01, 2022

Landec Corp. Receives Notice from Nasdaq Regarding Delayed Annual Report

Landec receives Nasdaq's notification on delayed annual report filing

Landec Corporation announced delayed annual 10-K filing

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Provides Revenue Guidance for the Full Year Fiscal 2023

VP & President of Lifecore exercised options to buy US$76k worth of stock.

Laughing Water Capital - Landec Corp. : A High Quality CDMO

Landec Corporation(NasdaqGS:LNDC) dropped from Russell 2000 Value-Defensive Index

Landec (NASDAQ:LNDC) Takes On Some Risk With Its Use Of Debt

Independent Director exercised options to buy US$70k worth of stock.

CEO, President & Director exercised options to buy US$269k worth of stock.

High number of new directors

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Reiterates Consolidated Earnings Guidance for the Fiscal Year 2022

Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet

High number of new directors

Independent Director recently bought US$104k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Provides Consolidated Revenue Guidance for Full Year Fiscal 2022

Price target increased to US$15.00

Consensus revenue estimates fall by 66%

Here's What's Concerning About Landec's (NASDAQ:LNDC) Returns On Capital

Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products

Landec Corporation Provides Earnings Guidance for the First Half, Second Half and Full Year of Fiscal 2022

First quarter 2022 earnings released: US$322 loss per share (vs US$0.38 loss in 1Q 2021)

Landec Still In Play As An Activist Investment

Independent Director Patrick Walsh has left the company

Consensus forecasts updated

Price target increased to US$14.40

Full year 2021 earnings released: US$1.12 loss per share (vs US$1.31 loss in FY 2020)

President of Lifecore exercised options to buy US$61k worth of stock.

Independent Director exercised options to buy US$106k worth of stock.

Is Landec (NASDAQ:LNDC) Using Too Much Debt?

Price target decreased to US$13.25

President of Lifecore recently bought US$106k worth of stock

Consensus EPS estimates fall to -US$1.03

Price target decreased to US$13.25

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.40 loss in 3Q 2020)

Landec Corporation Provides Revenue Guidance for the Full Fiscal Year 2021

Senior VP of Human Resources & Chief People Officer has left the company

New 90-day high: US$12.22

Landec Corporation Announces Resignation of Dawn Kimball as Senior Vice President and Chief People Officer, Effective March 12, 2021

Landec Corporation Mourns the Passing of Board Member Charles Macaluso

Independent Director has left the company